TP53 and cancer: Some of these mutant p53-specific siRNAs have been shown to elevate the dominant-negative activity of mutant p53 over the wild-type form, such as compound (240), thus sensitize tumor cells to therapeutic treatment, abrogating the addiction of tumor cells to mutant p53 for survival, promoting cell death of cancer cells expressing mutant p53, and retarding tumor growth in patient-derived xenografts without any side effects or organ toxicity.